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Abstract
Oncolytic viruses are able to speciﬁcally replicate, infect, and
kill only cancer cells. Their combination with chemotherapeu-
tic drugs has shown promising results due to the synergistic
action of virus and drugs; the combinatorial therapy is consid-
ered a potential clinically relevant approach for cancer. In this
study, we optimized a strategy to absorb peptides on the viral
capsid, based on electrostatic interaction, and used this strategy
to deliver an active antitumor drug. We used L-carnosine, a
naturally occurring histidine dipeptide with a signiﬁcant anti-
proliferative activity. An ad hoc modiﬁed, positively charged
L-carnosine was combined with the capsid of an oncolytic
adenovirus to generate an electrostatic virus–carnosine com-
plex. This complex showed enhanced antitumor efﬁcacy in vitro
and in vivo in different tumor models. In HCT-116 colorectal
and A549 lung cancer cell lines, the complex showed higher
transduction ratio and infectious titer compared with an
uncoated oncolytic adenovirus. The in vivo efﬁcacy of the
complex was tested in lung and colon cancer xenograft models,
showing a signiﬁcant reduction in tumor growth. Importantly,
we investigated the molecular mechanisms underlying the
effects of complex on tumor growth reduction. We found that
complex induces apoptosis in both cell lines, by using two
different mechanisms, enhancing viral replication and affecting
the expression of Hsp27. Our system could be used in future
studies also for delivery of other bioactive drugs. Mol Cancer Ther;
15(4); 1–10. !2016 AACR.
Introduction
Oncolytic adenoviruses are genetically modiﬁed adenoviruses
able to kill cells through the expression of cytotoxic proteins and
cell lysis (1). They are used for the treatment of cancer because of
their ability to replicate selectively in tumor cells (2).
It has been showed that oncolytic adenovirus, used as a single
agent, cannot fully eradicate tumors. Therefore, current strategies
involve the combination of oncolytic adenoviruses with chemo-
therapy, radiation, or immunotherapy.
During the recent years, considerable attention has been given
to the use of natural substances as anticancer drugs. The natural
antioxidant dipeptide L-carnosine belongs to this class of mole-
cules because it has been proven to have a signiﬁcant anticancer
activity both in vitro and in vivo (3). Anumber of biologic functions
have been recognized to this molecule, including antioxidant
activity, ability to chelate metal ions, inhibition of protein gly-
cosylation, anti-inﬂammatory, and antisenescence properties (4).
However, one of the limitations of the use of L-carnosine is that
the dose needed to arrest tumor progression exceeds the one
currently used in clinical settings (5, 6). The aim of this study was
to overcome this limitation by loading the carnosine on the
surface of an oncolytic virus to facilitate the entry of the peptide
into cancer cells. Consistent with this hypothesis, we found that a
Carnosine6K-coated oncolytic adenovirus displays an increased
transduction efﬁcacy and enhanced infectious titer compared
with the uncoated oncolytic adenovirus. In addition, both in vitro
and in vivo, we demonstrated that oncolytic virus complexed with
Carnosine6K showed an evident synergistic cytotoxic effect. These
results encourage the use of oncolytic adenoviruses coated with
modiﬁed carnosine for new therapeutic protocols to treat human
colon cancer and lung cancer. Moreover, this strategy could be
exploited for the delivery of many other bioactive drugs.
Materials and Methods
Cell lines
HCT-116 cell lines were purchased from DSMZ (Deutsche
Sammlung von Mikroorganismen und Zellkulturen) and
obtained from the cell bank of CEINGE Biotechnology in
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2014. They were constantly monitored in our laboratory by
microscopy morphology check and mycoplasma presence.
A549 lung cancer cell lines were purchased from the ATCC
(American Type Culture Collection) in 2012, and they were
checked formycoplasma and sterility before the use and routinely
monitored in our laboratory by microscopic morphology check.
CCD-112Sk, human skin ﬁbroblasts were kindly provided by Dr.
Santos from University of Helsinki (Helsinki, Finland) and no
authentication was done by the authors. Cells were cultured at
37!C and 5% CO2 in DMEM purchased from BioWhittaker
Classic Cell Culture Media, Lonza - VWR International s.r.l.,
supplemented with 10% FBS (Gibco Laboratories) and 1% pen-
icillin/streptomycin (Gibco Laboratories).
Virus preparation
The oncolytic adenoviruses utilized in this work were all
prepared according to standard protocols (7). Ad5D24-Rfp was
kindly provided by Dr. Masataka Suzuki from Baylor College of
Medicine (Houston, TX; ref.8) and it was propagated in our
laboratory.
Treatments
L-carnosine was purchased from Sigma-Aldrich, and dissolved
in PBS (Lonza-VWR International s.r.l.). A modiﬁed version of L-
carnosine (Carnosine6K), featuring six additional lysines at the C-
terminus, was purchased from GeneCust Europe Laboratoire de
Biotechnologie du Luxembourg S.A, and dissolved in PBS (Lonza-
VWR International s.r.l).
Complex formation
To saturate the surface of the oncolytic adenovirus, an excess of
Carnosine6K was used. Previous studies performed in our labo-
ratory showed that a ratio of 1:500 virus-to-peptide protein
amount was sufﬁcient to efﬁciently coat the viral surface. To allow
the formation of the complex between the oncolytic virus and
Carnosine6K, the two components were mixed and incubated at
room temperature for 15 minutes using MilliQ H2O at pH 7.4 as
buffer (9).
Zeta potential and dynamic light scattering analysis
Zeta potential analysis has been performed using 1" 1010 viral
particles (VP). All the samples were diluted in a volume of 800 mL
of MilliQ H20 at pH 7.4 and injected with a 1 mL syringe in the
capillary ﬂow cell to measure the electric surface charge of the
particles. An equilibration time of 120 seconds was set on the
software to allow the samples to stabilize at 25!C. For the
Dynamic light scattering analysis, the measurements were per-
formed with a ZetaSizer Nano Malvern.
Viability and transduction assay
Cell viability was determined by MTS according to the
manufacturer's protocol (Cell Titer 96 AQueous One Solution
Cell Proliferation Assay; Promega). Cells were seeded at a
density of 1 " 104 cells/well in 96-well plates and maintained
under appropriate condition. On the following day, cells were
infected using an oncolytic adenovirus Ad5D24Rfp encoding
for the red ﬂuorescent protein (100 VP, 10 VP, 1 VP, 0.1 VP)
and complex (100 VP, 10 VP, 1 VP, 0.1 VP). Red ﬂuorescence
was measured by Varioskan plate reader at 24, 48, and 72 hours
after the treatment.
Determination of the infectious titer
The determination of the infectivity was based on the visual
quantiﬁcation of infected cells. Upon the infection, the cell
synthesized excessive amounts of hexon proteins, which were
targeted by the ﬁrst antibody and diluted 1:2,000 for 1 hour at
room temperature in the dark (NB600-413, Novus Biologicals).
Then the cells were washed and incubated with the second Biotin-
SP–conjugated antibody and diluted 1:500 for 1 hour at room
temperature in the dark (115-065-062, Jackson Immuno
Research). After the incubation time, cells were washed and
incubated in the dark with Extravidin-peroxidase for 30 minutes
at room temperature (E2886-1ML, Sigma-Aldrich). Finally, cells
were treated with DAB (D3939-1SET, Sigma-Aldrich). The detec-
tion of infectious titer was made using microscope EVOS, and
each well was photographed (5 pcs) at ﬁve nonoverlapping sites.
Infected cells were counted using ImageJ and the infectious titer
was calculated according to the following equation:
Infectious titer: x
AðwellÞ11mL
AðfieldÞ1V
Where x ¼ number of infected (stained cells)
A (24 well) ¼ 190 mm2
A (ﬁeld) ¼ surface area of the ﬁeld
L ¼ dilution
V ¼ volume of virus dilution applied per well
Analysis of apoptotic and necrotic cell death
The amount of apoptotic and necrotic cells weremeasured after
24 and 48 hours postinfection with a TACS Annexin V-FITC kit
(Trevigen Inc.) and BD LSR II ﬂow cytometer according to man-
ufacturer's instructions.
Western blot analysis
Total extracts of HCT-116 and A549 cell lines were probed with
antibodies against p62 (H00008878-M01; mouse mAb from
Abnova), LC-3 (#2775, rabbit polyclonal antibody from Cell
Signaling Technology, Inc), HSP27 (ab2790, mouse mAb from
Abcam), and b-actin (sc-47778, mouse mAb from Santa
Cruz Biotechnology). The signals were detected using the ECL
kit (K-12045-D50, Advansta).
Quantitative PCR
qPCR for adenoviral E4 was performed as described previ-
ously (10).
RNA extraction and real-time PCR
Primer sequences used in qPCR are the following: IL8 forward:
50-AGACAGCAGAGCACACAAGC-30; IL8 reverse: 50-ATGGTTCC-
TTCCGGTGGT-30; actin forward: 50-CCTCACCCTGAAGTACC-
CCA-30; actin reverse 50-TCGTCCCAGTTGGTGACGAT -30
Animal experiments
All animal experiments were reviewed and approved by the
Experimental Animal Committee of the University of Helsinki
and the Provincial Government of Southern Finland. Mice were
obtained from Scanbur (Karlslunde, DK) at 5–7 weeks of age and
quarantined at least for 2 weeks before the study. Health status of
themice was frequentlymonitored and as soon as signs of pain or
distress were evident they were euthanized. For the efﬁcacy
experiment, human xenografts were established by injecting
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1" 106 A549 and HCT-116 cells s.c. into the ﬂanks of 5–7 week-
old female BALB/c nude mice (n ¼ 5 per group). Tumors (two
tumors permouse,&5" 5mm in diameter) were injected i.t. with
a volume of 50 mL for three times on days 0, 2, and 5 with 108
VP/tumor of Ad5D24CpG and control tumors were injected with
PBS only. The formula (length " (width) " 0.5) was used to
calculate the tumor volumes.Micewere euthanizedwhen a tumor
reached an average diameter of 15 mm.
Statistical analysis
Statistical signiﬁcance was determined by unpaired, two-tailed
Student t test using GraphPad Prism 6 (GraphPad Software, Inc.).
Therapeutic synergy was assessed using the fractional tumor
volume (FTV) method (11, 12).
Results
Modiﬁed L-carnosine can be coated on the capsid of an
oncolytic adenovirus through an electrostatic interaction
Themain purpose of this study was to develop a new system to
increase the amount of L-carnosine that is delivered to cells by
using virus as a carrier. In our laboratory,wedeveloped a system to
complexMHC-I–restricted peptideswith the viral capsid (9); here,
this system was adapted to combine virus and L-carnosine (Fig.
1A). L-carnosine was modiﬁed by adding a poly-lysine chain
(Carnosine6K) to confer to the peptide a positive charge and
consequently to allow the interactionwith the viral capsid that has
a negative charge (13). To conduct experiments, a serotype 5
conditionally replicating adenovirus that features a 24 base pair
deletion in E1A gene and enriched with CpG islands
(Ad5D24CpG) to stimulate the innate immune system through
toll-like receptor 9 (TLR9; ref.7) was used. It was already reported
that the complex presented good stability and no signiﬁcant
decrease of zeta potential was observed 15, 30, and 45 minutes
after incubation in the same conditions (MilliQ water ph 7.4).
Moreover, no aggregationwas seen at these time points (14). First,
the electric surface charge (zeta potential) of the complex was
analyzed to see whether the addition of the Carnosine6K was
inﬂuencing the charge and the size of the adenovirus–carnosine
complex (Fig. 1B). It was observed that after mixing Carnosine6K
with oncolytic adenovirus (1:500), the electric surface charge
became positive compared with the virus alone and Carnosine6K
alone (Fig. 1B). In addition to the net charge, the diameter of the
particles was also analyzed (Fig. 1C).
Carnosine6K-coated viruses display increased transduction
efﬁcacy, reduction in cell viability, and enhanced infectious
titer
To ensure that viral complex did not affect healthy cells, it was
tested inCCD-112Sk, human skin ﬁbroblasts, by performingMTS
cell viability assay to see whether any toxic effect was observed
(Supplementary Fig. S1).
Indeed, we wanted to examine whether the presence of Carno-
sine6K would have an effect on the transduction efﬁcacy of the
1- Modification of carnosine with 6K
2- Ad5D24CpG with carnosine6K
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Figure 1.
Oncolytic adenovirus as a carrier for active drugs. A, schematic representing the strategy to generate the carnosine–virus complex. A poly-lysine chain was
added to L-carnosine (Carnosine6K) to confer to the dipeptide a positive charge that favors the interaction with the negatively charged capsid of the
virus, as L-carnosine needs to be modiﬁed to be "absorbed" on the viral capsid. B and C, 1 " 1010 viral particles were conjugated with Carnosine6K at the ratio
of 1:500. After the reaction, zeta potential and particle size were measured.
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virus, we performeda transduction assay on twohuman tumor cell
lines A549, human lung cancer cell line, and HCT-116, human
colon cancer cell line. The transduction efﬁcacy of an RFP-expres-
sing oncolytic adenovirus (Ad5D24RFP) uncoated or complexed
was compared with modiﬁed L-carnosine (Ad5D24RFP-Carnosi-
ne6K). Transduction was assessed at 24, 48, and 72 hours post-
infection. Interestingly, at 72 hours from infection, the amount of
ﬂuorescent cells treated with complex was higher compared with
cells treated with naked oncolytic adenovirus (Fig. 2A and B).
To assess the cell killing activity of the complex, MTS cell
viability assays were performed. It was observed that at 100 VP,
complex displayed enhanced activity (Fig. 2C and D; P <0.001).
Then, the infectivity of the viruswas determined; Ad5D24CpG–
Carnosine6K complex was added as a single entity and
Ad5D24CpG and Carnosine6K added separately as a mix by
immunocytochemistry assay (ICC). The infectious titerwas higher
in the complex than in the virus alone using an infectious ratio of
10 VP/cell in both cell lines tested (Fig. 3A–D). In particular, in
A549 cells, one log higher infectious titer of Ad5D24CpG–Car-
nosine6K complex was found compared with the uncoated.
Carnosine6K-coated viruses can induce apoptotic and necrotic
cell death
Apoptosis is a physiologic response to exogenous and endog-
enous death signals. In particular, a prerequisite for tumor growth
is the inactivation of apoptotic pathwayswhich is also responsible
for therapy resistance (15). It has been demonstrated that
L-carnosine treatment at concentration 100 mmol/L is able to
induce late apoptosis only in a small number of cells (6). Thus,
the ability of the complex to induce apoptotic and necrotic cell
deathwas studied. The amount of Annexin-V-positive cells, that is
early apoptotic cells, and propidium iodide–positive cells (PI),
that is late apoptotic/necrotic cells 24 and 48 hours after the
treatment in A549 and HCT-116 (Fig 4A, B, D and E) cells was
measured. The levels of fold change at 48/24 hours of both the
early and the late apoptotic/necrotic cells were elevated in the
complex in both cell lines, compared with the virus alone and
L-carnosine alone with or without six lysines (Fig. 4C and F).
Oncolytic adenovirus loaded with L-carnosine induces
autophagy and enhances virus replication
It has been reported that virus-induced autophagy correlates
positively with virus replication and that the combination of an
adenovirus with an autophagy inducer improves antitumor
effects in cancer cells (16). L-carnosine has been deﬁned as a
mimic of rapamycin, an inhibitor of the mTOR, and so may be
able to induce autophagy (17). For these reasons, autophagy and
virus replication in HCT-116 and A549 cancer cell lines treated
with virus, Carnosine6K, and complex was investigated.
The autophagy was analyzed by assessing the expression of
LC3-I and LC3-II and p62 by immunoblotting assay. Conversion
of LC3-I to LC3-II was used as a marker to estimate autophagy
(18). p62 protein accumulates when autophagy is inhibited, and
decreases when autophagy is induced (19). We ﬁrst analyzed the
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Figure 2.
Effect of Carnosine6K-coated virus on cell transduction efﬁcacy and cell viability. A and B, the transduction efﬁcacy was evaluated by infection with an
oncolytic adenovirus encoding for the red ﬂuorescent protein (RFP) with or without Carnosine6K. RFP was measured using Varioskan plate reader 24, 48, and
72 hours postinfection. C and D, cell viability was performed by MTS assay on two cancer cell lines. '' , P < 0.01.
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effect of Carnosine6K at 0, 24, and 48 hours after treatment. As
shown in Fig. 5A, in HCT-116 cells, the amount of LC3-II readily
was increased 24 hours postaddition of Carnosine6K and was
further increased 48 hours after, compared with control cells. In
A549 cell lines, the Carnosine6K treatment revealed a better
conversion of LC3-I to LC3-II respect to untreated control cells
only 48 hours after treatment (Fig. 5A'). At the same time, the
intracellular levels of p62 were decreased in both cancer cells,
according to LC3-I conversion (Figs. 5A, A').
Next, the effect of the complex, adenoviruses alone, or the
combination of the adenovirus and Carnosine6K, reported in the
text as mix on autophagy, was investigated. Our results showed an
increase in the amount of LC3-II in HCT-116 cells infected with
complex, compared with adenovirus alone or mix. Despite the
autophagy was quite evident in A549, signiﬁcant differences were
notobserved in complex infectionwith respect to virus aloneormix.
Meanwhile, the intracellular p62 level was decreased at all time-
points (Fig. 5B'). To assess whether the autophagy would have an
inﬂuence on virus replication, the kinetics of viral genomes by
quantitative PCR was evaluated. We observed in HCT-116 an
increase of virus DNA after infection with complex at 24 and 48
hours, compared with the adenovirus alone or mix (Fig. 5C). In
A459 cells, no signiﬁcant differences were detected in virus DNA
amount (Fig. 5C'). These results demonstrated that in HCT-116
cells, Carnosine6K loaded to Ad5D24CpG improves antitumor
effect by enhancing the viral replicationandby inducing autophagy.
Carnosine6K-coated viruses affect Hsp27 expression,
modulating IL8 mRNA levels in A549 cells
Hsp27 is a stress-activated chaperone involved in protecting
cells from apoptosis in both normal and cancer cells. As many
other HSPs, Hsp27 is overexpressed in many cancer cells and
seems to have a role in mediating viral infection signaling (20).
We evaluated the effect of L-carnosine on Hsp27 expression in
HCT-116 and A549 cells treated with Carnosine6K or after infec-
tion with complex with respect to adenoviruses alone or mix. The
evaluation ofHsp27 expression highlights once again a difference
between two cell lines. Indeed, it was found that inHCT-116 cells,
the expression level of Hsp27 did not seem to be affected by
Carnosine6K treatment, although a slight increase in the expres-
sion after adenovirus infection (Fig. 6A andB)was observed. It has
been reported that the expression of HSPs could enhance the
replication of oncolytic adenovirus; then, our results may be in
agreement with the enhanced viral DNA replication in HCT-116
cells. In A549 cells, only Carnosine6K treatment reduced the
expression of Hsp27 in a time-dependent manner and this reduc-
tion was more evident after infection with complex and 48 hours
after the mix infection (Fig. 6C and D). This result could explain
why the complex ismore efﬁcient to induce apoptosiswith respect
to the adenovirus alone. Indeed, it is noted that knocking-down
Hsp27 expression by siRNA resulted in more apoptotic cell death
in A549 cells (21). The Hsp27 also mediates the adenoviral
infection signaling by forming a signalosome with p38 and
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NfkB-p65 inﬂuencing downstream expression of proinﬂamma-
tory mediators, particularly the expression of IL8, cytokine of the
CXC chemokine family. IL8 contributes to tumor growth and
progression, inducing cell growth and survival especially in lung
cancer (20).
Then, themRNA levels of IL8 by real-time PCR inHCT-116 and
A549 were evaluated. In HCT-116 cells, the IL8 mRNA level did
not change, after infection with complex or mix. On the other
hand, we found a signiﬁcant decrease of IL8 mRNA levels after
infection with complex in A549 cells (Fig. 6E and F). The stronger
antitumor effect of complex, observed in both cell lines, may be
generated from the sum of the adenovirus and L-carnosine activ-
ities or even a synergistic effect (the carnosine effect may increase
the efﬁcacy of adenovirus).
Complex displays increased efﬁcacy in vivo in a xenograftmodel
of lung and colon cancer and reduces the expression of Hsp27
The oncolytic activity of the complex was tested in a lung and
colon cancer xenograftmodel. Nudemice bearing A549 andHCT-
116 cell tumors in the ﬂanks were treated intratumorally with 1"
108 VP/tumor (or PBS) on days 0, 2, and 5 and the tumor growth
was followed over time. It was observed that the tumor growth
was signiﬁcantly (P <0.001 at day 18) reduced in both complex-
treated mice compared with the control virus and Carnosine6k
alone (Fig. 7A and B). Then, the therapeutic synergy between
Ad5D24CpG and Carnosine6K was calculated using fractional
tumor volume (FTV) method. Synergistic effect was found in
A549 mouse model treated with complex compared to mice
treated with mix. Interestingly, in HCT-116 cells, a synergistic
effect in complex and mix condition was found; however, the
effect was stronger in mice treated with the complex (Fig. 7C and
D; Supplementary Table S1).
Recent studies underline that the Hsp27 expression strongly
correlates with poor survival in patients with rectal cancer (22).
For this reason, the expression of Hsp27 was evaluated in protein
extracts obtained from xenograft tumors. Surprisingly, it was
found that the expression of Hsp27 was dramatically reduced in
both xenograft tumors after intratumoral administration of the
complex. (Fig. 7 E and F).
Discussion
In spite of encouraging clinical results, improvements to
enhance the efﬁcacy oncolytic adenoviruses are still needed
(23, 24). One strategy is to combine the viruses with chemo-
therapy (25). However, the uptake of drug-like molecules might
still be a problem. For this reason, the new anticancer strategies
aim to deliver and facilitate the uptake and intracellular accu-
mulation of drugs into cancer cells, while reducing the nonspe-
ciﬁc uptake into normal cells. To overcome this limitation, the
possibility to use the adenovirus as carrier for active molecules
was explored (3).
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Adenovirus capsid has been previously coated mainly with
polymers to shield the virus for recognition of receptors of the
innate immunity and antibodies, but our system is the ﬁrst
electrostatic strategy used for the delivery of active drugs by the
virus (26). In accord with pervious ﬁndings (13), enhanced
transduction and less receptor dependency of the positively
charged complex compared with naked virus was also observed
(13). Indeed, the percentage of transduction was mildly affected
by the complex; however, the complex group exhibits higher
amount of ﬂuorescent cells over other groups at 72 hours post-
infection. This could suggest that complex activity has been
improved by Carnosine6K presence, and its mechanism of action
is not directly related to the transduction as shown in vitro through
transduction and infectivity assays and in vivo efﬁcacy studies. We
havepreviously demonstrated that L-carnosine could represent an
adjuvant candidate for colon cancer treatment and the adenovirus
as carrier for L-carnosine has proved to be a good strategy to
improve the adenovirus activity. The role of L-carnosine in the
complex was to enhance anticancer effect when combined with
oncolytic adenovirus. We hypothesized that combined agents
could exhibit synergistic anticancer properties, as it is known that
oncolytic adenovirus are novel antitumor agents with the ability
to selectively replicate and lyse tumor cells while remaining
innocuous to the rest of the body (7) and L-carnosine alone has
antiproliferative cancer effect (3). Indeed, we found that the
complex formed by the interaction between L-carnosine and
adenovirus was able to induce apoptosis and necrosis at signif-
icantly lower concentration of L-carnosine compared with that
required for the drug alone. Interestingly, we did not observe a
signiﬁcant increase of efﬁcacy when Carnosine6K and oncolytic
adenovirus were added separately as a mix, perhaps because
L-carnosine uses virus as a carrier tomaximize cell entry, as shown
in in vitro cell viability assay. It has been shown that poly-lysine
linked to several different peptides and MHC-I restricted did not
affect the cell killing activity of the virus highlighting the speciﬁc
role of L-carnosine in our system.
In addition, molecular analysis performed on HCT-116 and
A549 cell lines demonstrate that the oncolytic virus coated with
modiﬁed L-carnosine improves the antitumor effect respect to
virus or L-carnosine alone.
This synergy wasmainly based on enhanced autophagy and on
expression of Hsp27. Indeed, it has been reported that Ad5
induces cell lysis through autophagy and that viruses may also
use autophagy-related vacuoles as ameans for newprogeny to exit
the infected cell (27). In addition, the combination of an adeno-
virus with an autophagy inducer correlates positively with virus
replication, improving the efﬁcacy of Ad-mediated oncolysis.
Therefore, we explored whether the oncolytic adenovirus loaded
to L-carnosine, amimic of rapamycin, improves antitumor effects
in cancer cells (16). LC3II conversion performed in HCT-116 and
in A549 cells demonstrates that the complex increases autophagy
promoting virus replication only in colon cancer cells (HCT-116).
In agreement with these results, we have found only in HCT-116
cell line, a signiﬁcant increase of viral particles, by qPCR, after
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complex infection. Despite the autophagy is quite evident in
A549, we did not observe any differences in complex infection
respect to virus alone or mix. In this cell line, we suppose that the
autophagy is associated to adenovirus infection probably
improved by its CpG islands. Indeed, some authors previously
reported that CpG motifs might induce autophagy in human
tumor cell lines by TLR9-dependent mechanism (28). The HSP
expression seems to have a crucial role not only in tumor cell
survival and proliferation but also in viral replication and in
mediating the viral infection signaling. Actually, several studies
supported the idea that cells with higher HSPs expression might
have more favorable environment for virus replication. Indeed,
HSP overexpression may change the level of some genes, which
are responsible for adenovirus life cycle in cells such as adenovirus
receptor (CAR), which affects the infection and replication of
adenovirus. It has been reported that HCT-116 cells have high
expression of Hsp27 (29) and we found that Hsp27 was more
expressed in HCT-116 compared with A549 cell line (unpub-
lished observations; Western blot analysis conducted in our
laboratory). The basal expression of Hsp27 might favor the
environment for virus replication and also exert antiapoptotic
function, helping the virus to form new virus particles in an early
phase of complex activity. These results are in agreement with the
hypothesis that HSP expression enhances oncolytic effect of
replicative adenovirus (30). In A549 cells, instead, we found a
reduction of Hsp27 protein level after complex infection. In this
cell line, we did not observe any difference in viral DNA replica-
tion. In addition, according to the assay for infectious titer, in
HCT-116 cells, we found a higher number of viral particles after
the Ad5D24CpG infection with respect to A549. On the basis of
these results, we supposed that the adenovirus enters into the
HCT-116 cell line with higher efﬁciency or that this cell line has
more favorable environment for virus replication.
It is noted that in lung tumor cells, Hsp27 expression is
correlated to resistance to apoptotic cell death (21). Consequent-
ly, we hypothesize that the antitumor effect of complex in A549
can be attributed, partially, toHsp27 reduction. In addition, it has
been evaluated also in IL8 mRNA levels, because a recent study
strongly suggested that Hsp27, p38, and NF-kB-p65 form a
signalosome in virus-infected cells inﬂuencing cytokines expres-
sion. It has been demonstrated that a siRNA of Hsp27 is able to
disrupt this association reducing the IL8 expression (20).
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Endogenous expression of IL8 has been found in various
human cancers, including AML, B-cell CLL, breast cancer, colon
cancer, cervical cancer, gastric cancer, Hodgkin lymphoma, and
ovarian, prostate, and lung cancers. Evidence shows that IL8
biologic activity in tumors and the microenvironment may con-
tribute to cancer progression, and in other circumstances to
induce antitumor response. This biologic response may be dif-
ferent in different types of human cancers (31). We found a
signiﬁcant decrease of IL8 mRNA only in A549 cells, a cell line
which overexpresses EGFR. IL8 is involved in tumor cell prolif-
eration via EGFR, and the IL8 decrease might explain the better
antitumor effect of complex (32, 33). In the end, we investigated
the in vivo efﬁcacy of the complex in human colon cancer and lung
cancer xenograft model. It has been demonstrated that the intra-
duodenal administration of L-carnosine decreases splenic sym-
pathetic nerve activity (splenic-SNA) and inhibits the prolifera-
tion of HCT-116 cell line implanted into athymic BALB/c nude
mice. In vivo data revealed that 1 mg/mL of L-carnosine solution
given in the drinking water from 6 to 22 days inhibited tumor
proliferation (34). Starting from these results, we evaluated that
the intratumoral administration of the complex resulted in a clear
tumor reduction and most of the tumors were fully eradicated
within 18 days after the virus injection. In tumor growth follow-
up studies, we observed that tumor growth of mice treated with
complex was signiﬁcantly suppressed compared with the mice
treated with virus alone. Surprisingly, we also found that the
expression of Hsp27 was dramatically reduced in both xenograft
tumors after intratumoral administration of the complex. This
result represents a promising indication, because recent studies
suggest the possibility of Hsp27 inhibition formolecular target in
cancer therapy.Molecular analysis is preliminary; however, it adds
somethingnew in theunderstanding of themolecularmechanism
underlying the development of an innovative methodology. In
conclusion, the results described in this study encourage the use of
Ad5D24CpG–Carnosine6K for new therapeutic protocols for the
treatment of cancer and in particular human colon cancer and
lung cancer. Moreover, the use of oncolytic adenoviruses loaded
with active drugs could be used as a novel drug delivery system for
cancer therapy.
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